This trial will test a new drug for type 2 diabetes with obesity and high cardiovascular risk, over 2 years with up to 27 visits.
- Overweight or Obesity
- Cardiovascular Disease
- Type 2 Diabetes
- Chronic Kidney Disease
1 Primary · 9 Secondary · Reporting Duration: Baseline to End of the Study (Approximately 104 Weeks)
Side Effects for
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
2620 Total Participants · 2 Treatment Groups
Primary Treatment: Orforglipron · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What site did they apply to?
|Clinical Research Professionals||18.4%|
|Diabetes and Endocrinology Specialists||20.4%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||7.5%|
How many prior treatments have patients received?
Why did patients apply to this trial?
- "Need help with weight loss"
- "Also am pre diabetic and haveCKD"
- "self preservation and quality of life"
- "I need to lose weight and keep it off."
- "I’ve just not had luck in losing weight."
What questions have other patients asked about this trial?
- "What do I need to do?"
- "How long do screning visits last?"
- "How long do screening visits take?"
- "What are the hours for screening appointments?"
- "What are the adverse effects? When does it start?"
How responsive is this trial?
Average response time
- < 2 Days
Most responsive sites:
- Clinical Research Professionals: < 24 hours
Typically responds via
Frequently Asked Questions
Is this experiment currently recruiting new participants?
"Affirmative. According to the clinicaltrials.gov platform, this medical trial is still recruiting patients; it was originally posted on April 3rd 2023 and had its most recent update on April 7th of that same year. It currently has 2620 participants from 319 different sites involved with the study." - Anonymous Online Contributor
How many locations are engaging in this research endeavor?
"Patients may join the trial at Cahaba Research - Pelham in Pelham, Arizona, Syed Research Consultants Llc in Sheffield, Arkansas and Aventiv Research in Mesa, California as well as an additional 319 sites." - Anonymous Online Contributor
Has the FDA sanctioned Orforglipron for use in clinical practice?
"After considering the Phase 3 trial data, our team at Power has judged Orforglipron to be a secure option with a score of 3 out of 3." - Anonymous Online Contributor
What is the total participant count for this research project?
"The sponsor of the research, Eli Lilly and Company, requires a total of 2620 patients to fulfill their clinical trial's inclusion criteria. This can be done by conducting trials out of Cahaba Research- Pelham in Pelham, Arizona and Syed Research Consultants Llc in Sheffield, Arkansas." - Anonymous Online Contributor